First compound
AOD-9604 BPC-157 Cagrilintide CJC-1295 (no DAC) / Modified GRF (1–29) CJC-1295 (no DAC) + Ipamorelin CJC-1295 (with DAC) DSIP Dulaglutide Epitalon / Epithalon Exenatide GHK-Cu GHRP-6 Hexarelin Ipamorelin KPV Liraglutide MOTS-c NAD+ Pramlintide PT-141 / Bremelanotide Retatrutide Selank Semaglutide Semax Sermorelin Setmelanotide SS-31 / Elamipretide Survodutide TB-500 Tesamorelin Thymosin Alpha-1 / Thymalfasin Tirzepatide and
Second compound
AOD-9604 BPC-157 Cagrilintide CJC-1295 (no DAC) / Modified GRF (1–29) CJC-1295 (no DAC) + Ipamorelin CJC-1295 (with DAC) DSIP Dulaglutide Epitalon / Epithalon Exenatide GHK-Cu GHRP-6 Hexarelin Ipamorelin KPV Liraglutide MOTS-c NAD+ Pramlintide PT-141 / Bremelanotide Retatrutide Selank Semaglutide Semax Sermorelin Setmelanotide SS-31 / Elamipretide Survodutide TB-500 Tesamorelin Thymosin Alpha-1 / Thymalfasin Tirzepatide
Comparing two neutral evidence records.
What this comparison does not mean
More sources do not mean a compound is safer, more effective, appropriate, or preferable.
Different records may have different evidence because the compounds, routes, and regulatory
histories differ.
i Educational reference only.
This page does not provide medical advice, dosing recommendations, diagnosis, treatment guidance, or a
substitute for a qualified clinician. Calculator results only transform values you enter.
Read the library notice
Aliquot Compound Library
Before you browse
Aliquot's Compound Library is an educational reference. Here is how to read and use it.
Educational, not medical advice
The library does not diagnose, treat, prevent, recommend a compound, or replace a licensed
clinician. Consult a qualified clinician for personal health decisions.
Evidence has boundaries
Summaries draw from cited public regulator records, peer-reviewed human studies, PubMed
records, and trial registrations. A citation does not make a claim conclusive.
No community health profiles
Aliquot does not collect community protocols or outcomes for this library. Calculator entries
remain in your browser tab and are not submitted or saved.
Content and reuse
Aliquot's original editorial text and presentation may not be copied, scraped, mirrored, or
redistributed without written permission. Linked sources remain subject to their publishers'
terms.